Skip to main content

Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma

Endocrine volume 49, pages 366–372 (2015)Cite this article

Abstract

Activating germline mutations in the RET proto-oncogene are responsible for about 98 % of the familial forms of medullary thyroid carcinoma (MTC), which represent 25 % of all MTC cases. The search for germline mutations in this gene is important for the recognition of hereditary forms of MTC and further identification of at-risk relatives who may benefit from early clinical intervention. Genotype–phenotype correlations are well established for most disease-causing RET mutations, allowing risk stratification. The association of a new RET variant with the MTC phenotype and familial predisposition requires the assessment of its functional and clinical significance. The aim of this study was to evaluate the oncogenic potential of two newly identified RET germline variants associated with late-onset MTC. In vitro functional assays were designed to address the transforming potential of novel RET variants, through their expression in non-transformed cells, and comparing their effect with wild-type RET. The new variants were identified in codons 515 (p.C515W) and 636 (p.T636M) located, respectively, in exons 8 and 11, thus resulting in amino acid substitutions in the extracellular region of the tyrosine kinase receptor RET. Through functional assays, we observed increased cell growth and proliferation, loss of contact inhibition, and a stimulation of cell migration, suggesting that these new RET variants hold some relevant transforming potential. The transforming potential of these novel RET variants was of low-grade, when compared to that of RET MEN2A-causing mutation p.C634R, probably explaining the mild phenotype characterized by late onset and low clinical aggressiveness.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. A. Cerrato, V. De Falco, M. Santoro, Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J. Mol. Endocrinol. 43, 143–155 (2009)

    Article  CAS  PubMed  Google Scholar 

  2. F.D. Gilliland, W.C. Hunt, D.M. Morris, C.R. Key, Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79, 564–573 (1997)

    Article  CAS  PubMed  Google Scholar 

  3. R.A. DeLellis, Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 94, 662–669 (2006)

    Article  CAS  PubMed  Google Scholar 

  4. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, H.K. van Amstel, C.J. Lips, I. Nishisho, S.I. Takai, D.J. Marsh, B.G. Robinson, K. Frank-Raue, F. Raue, F. Xue, W.W. Noll, C. Romei, F. Pacini, M. Fink, B. Niederle, J. Zedenius, M. Nordenskjöld, P. Komminoth, G.N. Hendy, L.M. Mulligan, The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575–1579 (1996)

    Article  CAS  PubMed  Google Scholar 

  5. L.M. Mulligan, C. Eng, C.S. Healey, D. Clayton, J.B. Kwok, E. Gardner, M.A. Ponder, A. Frilling, C.E. Jackson, H. Lehnert, Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6, 70–74 (1994)

    Article  CAS  PubMed  Google Scholar 

  6. L.M. Mulligan, D.J. Marsh, B.G. Robinson, I. Schuffenecker, J. Zedenius, C.J. Lips, R.F. Gagel, S.I. Takai, W.W. Noll, M. Fink, Genotype–phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J. Intern. Med. 238, 343–346 (1995)

    Article  CAS  PubMed  Google Scholar 

  7. E. Arighi, M.G. Borrello, H. Sariola, RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16, 441–467 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. J.E. Phay, M.H. Shah, Targeting RET receptor tyrosine kinase activation in cancer. Clin. Cancer Res. 16, 5936–5941 (2010)

    Article  CAS  PubMed  Google Scholar 

  9. G. Figlioli, S. Landi, C. Romei, R. Elisei, F. Gemignani, Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat. Res. 752, 36–44 (2013)

    Article  CAS  PubMed  Google Scholar 

  10. M.M. Moura, B.M. Cavaco, A.E. Pinto, R. Domingues, J.R. Santos, M.O. Cid, M.J. Bugalho, V. Leite, Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br. J. Cancer 100, 1777–1783 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. T. Fukuda, K. Kiuchi, M. Takahashi, Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J. Biol. Chem. 277, 19114–19121 (2002)

    Article  CAS  PubMed  Google Scholar 

  12. W.-H. Hsu, Y.-R. Yu, S.-H. Hsu, W.-C. Yu, Y.-H. Chu, Y.-J. Chen, C.-M. Chen, L.-R. You, The Wilms’ tumor suppressor Wt1 regulates Coronin 1B expression in the epicardium. Exp. Cell Res. 319, 1365–1381 (2013)

    Article  CAS  PubMed  Google Scholar 

  13. T.H.-Y. Leung, Y.-P. Ching, J.W.P. Yam, C.-M. Wong, T.-O. Yau, D.-Y. Jin, I.O.-L. Ng, Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl. Acad. Sci. U.S.A. 102, 15207–15212 (2005)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. P. Matos, C. Oliveira, S. Velho, V. Gonçalves, L.T. da Costa, M.P. Moyer, R. Seruca, P. Jordan, B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 135, 899–906 (2008)

    Article  CAS  PubMed  Google Scholar 

  15. H. Prazeres, J.P. Couto, F. Rodrigues, J. Vinagre, J. Torres, V. Trovisco, T.C. Martins, M. Sobrinho-Simões, P. Soares, In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocr. Relat. Cancer 18, 401–412 (2011)

    Article  CAS  PubMed  Google Scholar 

  16. R.A. Toledo, R. Hatakana, D.M. Lourenço, S.C. Lindsey, C.P. Camacho, M. Almeida, J.V. Lima, T. Sekiya, E. Garralda, M.S. Naslavsky, G.L. Yamamoto, M. Lazar, O. Meirelles, T.J.P. Sobreira, M.L. Lebrao, Y.A.O. Duarte, J. Blangero, M. Zatz, J.M. Cerutti, R.M.B. Maciel, S.P.A. Toledo, Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr. Relat. Cancer 22, 65–76 (2015)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. C.F. Ibáñez, Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 5, a009134 (2013)

    Article  PubMed Central  PubMed  Google Scholar 

  18. S.M. Wagner, S. Zhu, A.C. Nicolescu, L.M. Mulligan, Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo) 67(Suppl 1), 77–84 (2012)

    Article  Google Scholar 

  19. L.M. Mulligan, RET revisited: expanding the oncogenic portfolio. Nat. Rev. Cancer 14, 173–186 (2014)

    Article  CAS  PubMed  Google Scholar 

  20. M. Muzza, D. Cordella, J. Bombled, F. Guizzardi, Z. Francis, P. Beck-Peccoz, M. Schlumberger, L. Persani, L. Fugazzola, B. Bressac-de Paillerets, Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. Eur. J. Endocrinol. 162, 771–777 (2010)

    Article  CAS  PubMed  Google Scholar 

  21. F. Fazioli, G. Piccinini, G. Appolloni, R. Bacchiocchi, G. Palmonella, R. Recchioni, E. Pierpaoli, F. Silvetti, M. Scarpelli, M. Bruglia, R.M. Melillo, M. Santoro, M. Boscaro, A. Taccaliti, A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. Thyroid 18, 775–782 (2008)

    Article  CAS  PubMed  Google Scholar 

  22. R. Elisei, B. Cosci, C. Romei, L. Agate, P. Piampiani, P. Miccoli, P. Berti, F. Basolo, C. Ugolini, R. Ciampi, Y. Nikiforov, A. Pinchera, Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J. Clin. Endocrinol. Metab. 89, 5823–5827 (2004)

    Article  CAS  PubMed  Google Scholar 

  23. F. Lesueur, A. Cebrian, A. Cranston, J. Leyland, T.M. Faid, M.R. Clements, M. Robledo, J. Whittaker, B.A.J. Ponder, Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J. Clin. Endocrinol. Metab. 90, 3454–3457 (2005)

    Article  CAS  PubMed  Google Scholar 

  24. P. Kaldrymides, N. Mytakidis, T. Anagnostopoulos, M. Vassiliou, A. Tertipi, M. Zahariou, T. Rampias, G. Koutsodontis, I. Konstantopoulou, A. Ladopoulou, T. Bei, D. Yannoukakos, A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clin. Endocrinol. 64, 561–566 (2006)

    Article  CAS  Google Scholar 

  25. I. Huguet, T. Cranston, L. Walker, N. Karavitaki, A.B. Grossman, A patient with an apparently sporadic pheochromocytoma with a rearranged during transfection codon 635 variant: a mild form of multiple endocrine neoplasia type 2? Endocr. Pract. 20, e65–68 (2014)

    Article  PubMed  Google Scholar 

  26. S. Kjaer, K. Kurokawa, M. Perrinjaquet, C. Abrescia, C.F. Ibáñez, Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 25, 7086–7095 (2006)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr Diogo Freitas dos Santos for referring us patient A. Moreover, we thank Dr. Masahide Takahashi for kindly donating pcDNA3.1/Zeo(+) plasmid carrying the human wild-type RET cDNA sequence. We also thank Paulo Matos (FCUL, Lisboa) as well as Bruno Cardoso (IPOFG, Lisboa) for generously providing pRK5-Myc-H-RASV12-expressing construct, pERK1/2 and pS6 antibodies.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Unidade de Investigação de Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Rua Professor Lima Basto, 1099-023, Lisbon, Portugal

    A. L. Silva, F. Carmo, M. M. Moura, R. Domingues, C. Espadinha, V. Leite, B. Cavaco & M. J. Bugalho

  2. Serviço de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023, Lisbon, Portugal

    V. Leite & M. J. Bugalho

  3. iNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/NMS, IPOLFG and ITQB), Av. República , Qta. do Marquês, 2780-157, Oeiras, Portugal

    A. L. Silva, M. M. Moura, R. Domingues, V. Leite, B. Cavaco & M. J. Bugalho

  4. NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056, Lisbon, Portugal

    V. Leite, B. Cavaco & M. J. Bugalho

Authors
  1. A. L. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Carmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Moura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Domingues
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Espadinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Leite
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Cavaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. J. Bugalho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. L. Silva.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Silva, A.L., Carmo, F., Moura, M.M. et al. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. Endocrine 49, 366–372 (2015). https://doi.org/10.1007/s12020-015-0559-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0559-0

Keywords

  • Thyroid
  • Oncogenic potential
  • MTC
  • MEN2
  • RET